Is Thymosin Alpha-1 Legal in New York? How to Access It Legally
HealthRX.com
Thymosin alpha-1 is not FDA-approved and is in no state pharmacy list
At a glance
- FDA approval / None. No US marketing application; four orphan designations are not approvals [1]
- State-licensed pharmacy list / Not in any category; FDA proposed against adding it [2][4]
- Outsourcing facility list / Category 3, 'nominated without adequate support' [3]
- Federal advisory vote / 4 yes, 17 no on both the free base and the acetate, December 2024 [4]
- HHS October 2026 draft policy / Not among the six peptides it names [5]
- Approved outside the US / Italy, India and Hong Kong, per FDA [1]
- Sport / Not named on WADA's 2026 Prohibited List [6]
What its US status is
Thymosin alpha-1 (thymalfasin) is a 28-amino-acid peptide with an acetylated N-terminal end, originally isolated from thymosin fraction 5. Zadaxin is the brand of the finished 1.6 mg injection sold outside the US, and it is not interchangeable with bulk thymosin alpha-1 powder [1]. It is a different peptide from thymosin beta-4 and TB-500 [6].
A Drugs@FDA search found no US marketing application for it, and its four orphan drug designations are a separate process, not approvals [1]. FDA lists national authorisations in Italy (adjuvant to influenza vaccination in immunocompromised people), India (chronic hepatitis B in adults 18 or older with compensated liver disease and virus replication) and Hong Kong [1]. The European Medicines Agency holds only an orphan designation, for hepatocellular carcinoma, which is not a marketing approval [1]. Two older reviews by authors tied to the Zadaxin developer say it is approved in 'over 35 countries' (2009) and 'more than 30 countries' (2007) [7][8].
Questions worth asking
Can a New York pharmacy compound it?
Thymosin alpha-1 is not in any of the three categories on FDA's list for state-licensed pharmacies and physicians (updated 14 May 2026) [2]. On the outsourcing facility list (updated 21 March 2025) it is in category 3, 'nominated without adequate support', and FDA's category 1 policy of generally not acting against compounders does not apply to it [3][2]. On 4 December 2024 the Pharmacy Compounding Advisory Committee voted 4 yes and 17 no, with no abstentions, on both the free base and the acetate. Members who voted no cited no compelling evidence of clinical effectiveness and safety, and FDA proposed that it not be added to the pharmacy list [4].
Thymosin alpha-1 was previously in category 2 (significant safety risks) and now sits in FDA's 'nominated but withdrawn' table because the nominators withdrew it [9]. FDA still posts its concerns: immunogenicity risk for certain routes of administration, peptide-impurity and characterisation problems, and safety information the agency called inadequate to understand the extent of any safety issues [9]. Thymosin alpha-1 is also not among the six peptides named in HHS's October 2026 draft enforcement-discretion policy, which lists BPC-157, epitalon, KPV, MOTS-c, Semax and TB-500 [5].
Is it prohibited in sport?
Thymosin alpha-1 is not named on WADA's 2026 Prohibited List [6]. WADA does name thymosin-beta-4 and its derivatives such as TB-500 under S2.3 growth factors, which is a different peptide. The S0 catch-all covers only substances with no approval from any governmental health authority, and thymosin alpha-1 is approved in some countries [6][1].
What is known about dosing and safety
No US-approved dose exists. In Italy, the Zadaxin 1.6 mg finished injection is labeled for subcutaneous or intramuscular use twice weekly for 4 weeks starting at the first vaccination, repeated from week 8 to week 12 at the second vaccination. That is an Italian regimen for the branded product, not a dose for compounded or bulk thymosin alpha-1. The Italian label says it is not for children, is contraindicated in pregnancy and breastfeeding, and calls for caution in people with allergies or autoimmune disease and with other immune-modulating drugs [1].
A 2026 Cochrane review of 10 randomised trials in 1,349 adults with chronic hepatitis B rated the evidence very low certainty, and the reviewers said they were 'not sure' thymosin alpha-1 helps [10]. The review found thymosin alpha-1 may have caused fewer serious adverse events than comparison treatments (risk ratio 0.72, 95% CI 0.53 to 0.99; 5 trials, 1,056 people; low-certainty evidence) [10].
Check what you know
Question 1 of 3
Score: 0 right, 0 of 3 answered
Frequently asked questions
Is thymosin alpha-1 legal in New York?
Is thymosin alpha-1 FDA-approved?
What is its status on FDA's compounding lists?
Where is thymosin alpha-1 approved?
Is thymosin alpha-1 banned in sport?
Reader questions
What people actually ask
Short answers drawn from the sources this article cites.
Is thymosin beta-4 legal?
No US legal status is given for thymosin beta-4 itself. WADA names thymosin-beta-4 and its derivatives such as TB-500 under S2.3 growth factors, and TB-500 is among the six peptides named in HHS's October 2026 draft enforcement-discretion policy. Thymosin beta-4 is a different peptide from thymosin alpha-1.
Where to inject thymosin alpha 1?
No injection site is specified for compounded or bulk thymosin alpha-1, and no US-approved dose exists. The only route described comes from Italy's label for the branded Zadaxin 1.6 mg injection: subcutaneous or intramuscular use twice weekly for 4 weeks, starting at the first vaccination. That is not a dose for compounded or bulk product, and the label says it is not for children.
References
Show all 10 referencesHide references
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.
- Official web page.
- World Anti-Doping Agency.
- Goldstein AL, Goldstein AL. From lab to bedside: emerging clinical applications of thymosin alpha 1. Expert Opin Biol Ther. 2009;9(5):593-608.
- Tuthill C. Issues in pharmaceutical development of thymosin alpha1 from preclinical studies through marketing. Ann N Y Acad Sci. 2007;1112:351-6.
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
- Naing C, Ni H, Aung HH, Aye SN, Nikolova D, Poovorawan Y, et al. Thymosin-ɑ1 for people with chronic hepatitis B. Cochrane Database Syst Rev. 2026;9(9):CD014610.